[HTML][HTML] HER2 testing: current status and future directions
EA Perez, J Cortés, AM Gonzalez-Angulo… - Cancer treatment …, 2014 - Elsevier
Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical
for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology …
for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology …
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists …
Purpose To update the American Society of Clinical Oncology (ASCO)/College of American
Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor …
Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor …
Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17
S Vranic, B Teruya, S Repertinger, P Ulmer… - Cancer, 2011 - Wiley Online Library
BACKGROUND: The current study was performed to determine the impact of polysomy 17
on the interpretation of HER2 testing of invasive breast carcinomas using fluorescent in situ …
on the interpretation of HER2 testing of invasive breast carcinomas using fluorescent in situ …
Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
J Lehmann-Che, F Amira-Bouhidel, E Turpin… - British journal of …, 2011 - nature.com
Background: Immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) are
currently the most commonly used methods to assess HER2 status. PCR-based assays …
currently the most commonly used methods to assess HER2 status. PCR-based assays …
Defining the Sister Rat Mammary Tumor Cell Lines HH-16 cl.2/1 and HH-16.cl.4 as an In Vitro Cell Model for Erbb2
Cancer cell lines have been shown to be reliable tools in genetic studies of breast cancer,
and the characterization of these lines indicates that they are good models for studying the …
and the characterization of these lines indicates that they are good models for studying the …
HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
PP Advani, JA Crozier, EA Perez - Biomarkers in medicine, 2015 - Taylor & Francis
Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is
now universally recommended as part of evaluation of invasive breast cancer. HER2 testing …
now universally recommended as part of evaluation of invasive breast cancer. HER2 testing …
ERBB2 in Cat Mammary Neoplasias Disclosed a Positive Correlation between RNA and Protein Low Expression Levels: A Model for erbB-2 Negative Human Breast …
Human ERBB2 is a proto-oncogene that codes for the erbB-2 epithelial growth factor
receptor. In human breast cancer (HBC), erbB-2 protein overexpression has been …
receptor. In human breast cancer (HBC), erbB-2 protein overexpression has been …
[HTML][HTML] Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer
X Pu, J Shi, Z Li, A Feng, Q Ye - Pathology-Research and Practice, 2015 - Elsevier
It has been proven that chromosome 17 centromere (CEP17) amplification causes
misleading human epidermal growth factor receptor 2 (HER2) gene fluorescence in situ …
misleading human epidermal growth factor receptor 2 (HER2) gene fluorescence in situ …
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer …
G Zoppoli, A Garuti, G Cirmena, LV di Cantogno… - Journal of Translational …, 2017 - Springer
Background Immunohistochemistry (IHC) and fluorescent-in situ hybridization (FISH) are
standard methods to assess human epidermal growth factor receptor 2 (HER2) status in …
standard methods to assess human epidermal growth factor receptor 2 (HER2) status in …
[HTML][HTML] Evaluation of HER2 gene status in breast cancer samples with indeterminate fluorescence in situ hybridization by quantitative real-time PCR
V Koudelakova, J Berkovcova, R Trojanec… - The Journal of Molecular …, 2015 - Elsevier
Administration of drugs targeting HER2 (official symbol ERBB2) is an important component
of therapy for breast cancer patients with HER2 amplification/overexpression as determined …
of therapy for breast cancer patients with HER2 amplification/overexpression as determined …